What antibiotics, other than doxycycline (Vibramycin), are used to treat Lyme disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternative Antibiotics for Lyme Disease Treatment

For patients who cannot take doxycycline, the recommended first-line alternatives for Lyme disease treatment are amoxicillin (500 mg three times daily for adults) or cefuroxime axetil (500 mg twice daily for adults) for 14 days. 1, 2

First-Line Alternatives to Doxycycline

Oral Options

  • Amoxicillin: 500 mg three times daily for adults or 50 mg/kg/day in 3 divided doses for children (maximum 500 mg per dose) for 14-21 days 1, 3
  • Cefuroxime axetil: 500 mg twice daily for adults or 30 mg/kg/day in 2 divided doses for children (maximum 500 mg per dose) for 14-21 days 1, 3

Parenteral Options (for neurological involvement)

  • Ceftriaxone: 2 g once daily IV for adults or 50-75 mg/kg/day for children (maximum 2 g) 1, 2
  • Cefotaxime: 2 g IV every 8 hours for adults or 150-200 mg/kg/day divided into 3-4 doses for children 1, 2
  • Penicillin G: 18-24 million units per day IV divided every 4 hours 2

Second-Line Options (Macrolides)

Macrolide antibiotics are less effective than first-line options and should only be used when patients cannot tolerate doxycycline, amoxicillin, and cefuroxime axetil 1, 4:

  • Azithromycin: 500 mg daily for adults or 10 mg/kg/day for children (maximum 500 mg) for 7-10 days 1, 4
  • Clarithromycin: 500 mg twice daily for adults or 7.5 mg/kg twice daily for children (maximum 500 mg per dose) for 14-21 days 1, 4
  • Erythromycin: 500 mg four times daily for adults or 12.5 mg/kg 4 times daily for children (maximum 500 mg per dose) for 14-21 days 1, 4

Treatment Selection Algorithm

  1. First assessment: Can the patient take doxycycline? (contraindicated in pregnancy, lactation, children <8 years)

    • If yes: Use doxycycline (first choice)
    • If no: Proceed to step 2
  2. Second assessment: Can the patient take beta-lactams (amoxicillin or cefuroxime)?

    • If yes: Use amoxicillin or cefuroxime axetil
    • If no: Proceed to step 3
  3. Third assessment: Does the patient have neurological involvement?

    • If yes: Use IV ceftriaxone, cefotaxime, or penicillin G
    • If no: Use a macrolide (azithromycin, clarithromycin, or erythromycin)

Important Considerations

  • Patients treated with macrolides should be closely monitored as these antibiotics have lower efficacy compared to first-line options 1, 4
  • First-generation cephalosporins (e.g., cephalexin), fluoroquinolones, carbapenems, vancomycin, metronidazole, and tinidazole are ineffective against B. burgdorferi and should not be used 2
  • A recent network meta-analysis found that oral amoxicillin, oral azithromycin, injectable ceftriaxone, and injectable cefotaxime were effective for treating Lyme disease 5
  • For neurological manifestations of Lyme disease, parenteral therapy with ceftriaxone is preferred over oral antibiotics 1, 2
  • For Lyme carditis in outpatients, oral antibiotics are preferred, while hospitalized patients may initially receive IV ceftriaxone until clinical improvement 1

Treatment Duration

  • Standard duration for oral therapy in early Lyme disease is 14 days 3, 4
  • For β-lactam antibiotics (amoxicillin, cefuroxime axetil), a full 14-day course is recommended due to their shorter half-life 3, 4
  • For Lyme carditis, 14-21 days of total antibiotic therapy is suggested 1

Common Pitfalls to Avoid

  • Using first-generation cephalosporins like cephalexin, which are ineffective against B. burgdorferi 2, 3
  • Prescribing fluoroquinolones, which lack efficacy against Lyme disease 2
  • Using long-term antibiotic therapy beyond recommended durations, which lacks supporting data and may cause harm 2, 6
  • Failing to consider co-infections with Babesia microti or Anaplasma phagocytophilum in patients with persistent symptoms despite appropriate therapy 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Chronic Lyme Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Children with Borrelia burgdorferi (Lyme Disease)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Preferred Treatment for Erythema Migrans

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.